Armata Pharmaceuticals
ARMP | AMEX
$2.99
-$0.88 (-22.74%)
At close: Nov 16, 2026, 4:00 PM ET
$2.90
-$0.09 (-3.01%)
After-hours:
Nov 16, 2026, 4:42 PM ET
-22.74%
(1D)No price chart data available for 1D timeframe.
Rating
30.8
-14.0 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #768/1021 (Top 75%)
Key Statistics
Market Data
Market Cap $111.21M
1D Range
2.98 4.13
52W Range
2.78 14.80
Valuation (TTM)
PE -0.42
PB -0.64
EV/EBITDA -4.10
Valuation (NTM)
Forward PE N/A
Forward PEG 0.02
Price Target $15.00
Cash Flow
FCF Yield -24.1%
SBC Adj. FCF Yield -30.7%
SBC Impact -27.2%
Margins
Gross Margin 75.0%
Operating Margin -622.9%
FCF Margin -415.2%
Growth (CAGR)
Revenue 3Y | 5Y 16.9% |
10.2%
Dil EPS 3Y | 5Y -81.3% |
-46.1%
FCF 3Y | 5Y 23.7% |
11.1%
Returns
ROA -131.0%
ROE 58.1%
ROIC -50.0%
Financial Health
Net Debt
$203.15M
Current Ratio 0.12
Interest Coverage -1.64
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections...
Sector Healthcare
Industry Biotechnology
Employees 61
IPO Date May 20, 1994
Website www.armatapharma.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 12, 2026
EPS
-$0.24
Beat +56.76%
YoY:
+67.57% REV
$3.17M
Beat +604.67%
YoY:
+173.60%Next Earnings
Mar 24, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$15.00
Upside
+401.67%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ARMP